Baseline HIV-1 resistance data are important for resistance monitoring purposes especially in regions initiating large-scale antiretroviral treatment programs. We examined 40 protease and 35 reverse transcriptase amino acid sequences of HIV-1 subtype C from drug inexperienced patients from rural settings in South Africa for resistance mutations. Samples were collected between 2001 and 2004 prior to the availability of antiretrovirals through public health institutions. Ninety-five percent of patients had no major mutations in the protease gene, although substitutions M46L (2.5%) and G73S (2.5%), which according to the Stanford Genotypic Resistance Interpretation Algorithm are considered major mutations, were detected. In addition, a high prevalence of minor mutations was observed in the protease, with at least three minor resistance-associated mutations in 37% of the isolates. An isoleucine insertion at codon 37 was detected in one sequence. Most of the RT sequences were wild-type, although V118I (8.5%) and Y318F (5.7%) associated with resistance to lamivudine and nevirapine, respectively, were observed. Our data suggest that major resistance mutations among the drug-inexperienced population in South Africa may be rare, and routine resistance testing before the initiation of therapy in this initial stage of the treatment program may not be necessary.
S
OUTH AFRICA HAS ONE OF THE HIGHEST HIV prevalence rates in the world with an estimated 5 million people infected. 1 Transmission is largely heterosexual, with a smaller proportion of infections occurring as a result of mother-to-child transmission. The predominant HIV-1 subtype is subtype C, with rare cases of intersubtype recombinants. 2, 3 Prior to 2004 antiretroviral drugs (ARV) were available only through private health care schemes in South Africa, and due to the scarcity and prohibitively high cost the majority of patients could not afford them. A national ARV treatment program was initiated in April 2004 to provide drugs to adults with a CD4 count of less than 200/l or a WHO stage 4 clinical condition, and to children with recurrent hospitalization due to HIV-related disease. The national drug regimen guideline stipulates the use of stavudine, lamivudine, and efavirenz as the first-line therapy for adults who have never been exposed to antiretrovirals, with nevirapine replacing efavirenz for women of child-bearing age. The second-line therapy comprises zidovudine, didanosine, and lopinavir/ritonavir. 4 The rapid development of resistant HIV primary isolates due to drug pressure is a universal phenomenon, irrespective of subtype. 5 The determination of a regimen based on the genetic resistance profiles of patients' viruses prior to the initiation of therapy generally correlates with a better outcome, compared to the absence of such resistance data. 6 However, genotyping is expensive and beyond the capacity of many health delivery facilities in the developing world. Information regarding the presence of resistant viruses is important in tailoring combina-tion regimens or to decide whether to prescribe resistance testing prior to initiation of therapy. We had previously reported on the genetic and phenotypic characteristics of prevalent viruses from the Limpopo Province. 7 To further contribute to the baseline genetic information of HIV-1 in South Africa, particularly from rural regions where few data exist, we examined the protease and reverse transcriptase genes of HIV-1 isolates from drug-naive individuals for drug resistance-related mutations and polymorphisms.
Blood was collected from 53 drug-inexperienced HIV antibody-reactive individuals from Limpopo and Gauteng provinces. Twenty-nine were obtained from rural Bela Bela (Limpopo) in August 2001, and 24 from Ga-Rankuwa (Gauteng) between October 2002 and January 2004. Plasma aliquots were stored at Ϫ80°C. The study subjects comprised 36 females and 17 males within the age range of 20-53 years. Signed informed consent was obtained from each patient prior to blood collection. Ethical approval was granted by the Institutional Research Committees on human subjects of the University of Venda, Thohoyandou, South Africa and the University of Limpopo Medunsa Campus, Pretoria, South Africa.
Viral RNA was isolated using the Viral mini RNA assay (Qiagen). A one-tube reverse transcriptase polymerase chain reaction (PCR) was performed with AMV RT (Roche) and Taq DNA polymerase (Invitrogen), followed by a nested PCR to generate an approximately 1.4-kb product comprising the entire protease (PR) gene and at least the first 900 base pairs of the reverse transcriptase (RT). The first round primers were (Pol1C) 5Ј-GAA GGA CAC CAA ATG AAA GAC TGT AC-3Ј and (RTRv) 5Ј-T GAC CCATCA AAA GAC TTG ATAGCT GAAATA-3Ј and the nested primers were (GagP1) 5Ј-CAA GGG GAG GCC AGG GAA TTT-3Ј and (Pol2R) 5Ј-CAT GGA GTA TAT TAT GAC CCA TCA-3Ј. Amplification of the expected product was successful for 42 samples. Failure to amplify 11 samples may be due to low viral load. The PCR products were purified either with QIAquick PCR purification kit (Qiagen) or Centricon (Millipore), and direct populationbased sequencing was performed on both strands with the BigDye terminator kit on ABI Prism 377 (Applied Biosystems) using Taq DNA polymerase. The PCR cycling conditions and sequencing primers were as previously reported. 7 Sequences were edited and predicted amino acids translated with SeqMan II (DNASTAR) software. Forty PR and 35 RT gene fragments were successfully edited. Due to poor sequence quality two PR and seven RT sequences could not be edited reliably and were therefore excluded from the analysis.
Genetic distances were calculated according to the Kimura two-parameter method. Nucleotide sequences of test viruses were aligned with reference sequences obtained from the GenBank with the Mega software. A phylogenetic tree was generated by the neighbor-joining method after gaps were stripped. Reliability of the tree was assessed by a bootstrapping of 1000 replicates. Figure 1 shows that 40 of the protease sequences clustered with HIV-1 subtype C references with high bootstrap values indicating that they are subtype C. A similar clustering was observed with the RT sequences (data not shown).
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The 40 clade C protease sequences were used to create a consensus sequence using the Seqpublish program (www.hiv.lanl. gov/content/hiv-db/HTML/tools.html) that was then compared to the overall subtype C consensus and the clade B consensus obtained from the GenBank (Fig. 2) . The alignment shows that the consensus was identical to the global subtype C consensus but differs from the subtype B consensus at eight residues (T12S, I15V, L19I, M36I, R41K, H69K, L89M, and I93L). Considering the first 300 amino acids in the RT, a length common to all the sequences, their consensus was identical to the global subtype C consensus except at position G123S, but differed from the global subtype B consensus at 17 positions (V35T, E36A, S48T, K122E, D123S, K173A, D177E, T200A, Q207E, R211K, V245Q, A272P, K277R, T286A, E291D, V292I, and I293V) (Fig. 3) .
Nucleotide sequences were analyzed according to the Stanford HIV genotypic Resistance Interpretation Algorithm to detect mutations associated with resistance to PR and RT inhibitors. This interactive program based on a subtype B consensus compares codons of query sequences with resistance coding nucleotides. The reference resistant sequences in the database are derived from patients failing therapy, and from phenotypic assays. Mutations that on their own result in resistance are referred to as major mutations, while mutations that reduce susceptibility in association with other mutations are referred to as minor mutations. Polymorphisms, which are naturally occurring amino acid changes at sites associated with resistance, were also examined. Among the PR from the present study, the major mutations M46L (together with the minor mutations 136M, V77I, V82I, and 193L) occurred in one sample (04J8832ZA); G73S, was detected in sample 01PB34ZA and was accompanied by the minor mutations K20R, D60E, and I93L. One PR sequence (01PB16ZA) had an isoleucine insertion at codon 37, together with the minor mutations M36T, D60E, L63S, and I93L (Fig.  2) . Insertions in the PR are rare, and have not been shown to influence drug resistance. 9 Fifteen (37.5%) of the viruses harbored at least three known minor drug resistance mutations or mutations of unknown significance such as K20R, M36I, and L63P/V. Position 63 was the most polymorphic with 45% of the isolates harboring substitutions at this position. Resistant-related mutations in the RT comprised V118I, L210F, and Y318F (not shown). These occurred as dual substitutions, V118I/Y318F (01PB6ZA and 01PB11ZA) and L210F/Y318F (01PB43ZA). One sample (01PB34ZA) had mutations in both the PR and RT (G73S and V118I). Observed polymorphisms included K20R, BESSONG ET AL. 1308
FIG. 2.
Distribution of amino acid mutations and polymorphisms among protease sequences of HIV-1 subtype C isolates from South African drug naive patients. The test sequences are aligned against a consensus (Consensus_c) generated from among them. CONSENSUS_B and CONSENSUS_C are the global HIV-1 subtype B and C consensus sequences. Dots indicate identical amino acids. Regions in gray represent identified major and minor resistance mutation loci. Isolate 01PB16ZA is depicted harboring an isoleucine insertion at codon 37. M36I, V71I, I93L, A98S, and V179I. These amino acid changes reduce susceptibility in subtype B viruses, but occur naturally in non-B subtypes. The nucleotide codons introducing the observed resistance-related substitutions in these subtype C sequences also occur in subtype B sequences. Details of the observed mutations and polymorphisms associated with drug resistance and their frequencies are shown in Table 1 .
Previous studies in South Africa have shown that drug-resistant viruses among naive patients are not common. No known drug resistance mutations against zidovudine and multiple nucleosides were found in 37 RT sequences from drug pregnant women from Soweto. 10 Apart from minor mutations such as L10I, K20R, M36I, M63P, and V77I in the PR Gordon et al. 11 did not find any known major PR resistance mutations in 72 patients from KwaZulu Natal. Similarly, no major or minor resistant mutations against nucleoside RT inhibitors were identified, although K103N, G190A that causes resistance to nonnucleoside RT inhibitors was detected in two epidemiologically linked patients, and A98G in a third patient. Nevertheless, as more patients gain access to antiretrovirals, there is a need to monitor the development of resistance, using broader and more diversified sample populations.
Despite the beneficial effects of PR and RT inhibitors in improving the quality of life of AIDS patients, the selection and evolution of resistance variants are inevitable. The presence of resistance viruses complicates treatment options, particularly when they occur in previously drug inexperienced patients. In the present study, the significant PR mutations M46L and G73S, according to the Stanford HIV Genotypic Resistance Interpretation Alogrithn, were each detected in two different patients. However, M466 is considered a major mutation to indinavir only and G73S a minor mutation by the International Aids Society guidelines, another generic drug resistance interpretation source with wide application. 11 M46L is usually selected early on and also leads to high level resistance to ritonavir 12 and is associated with reduced susceptibility to lopinavir. 13 One report indicates that G73S emerges following a switch from saquinavir to indinavir 14 and another characterizes it as conferring reduced susceptibility to both saquinavir and nefinavir. 15 Regarding resistance to RT inhibitors, V118I, L210F, and Y318F were detected. Y318F is usually associated with low level resistance to nevirapine and acts synergistically with K103N and Y181C to confer higher level resistance to delavirdine and efavirenz than seen with either of these mutations alone. 16 V118I often induces cross-resistance to lamivudine in the presence of 41L/67N/210W/215Y. 17 In our samples two out of three times V118I occurred with Y318F. It would be inter- esting to phenotypically determine the significance of this apparent association. It is interesting that L210F was also seen. This is rare in HIV-1-C and is of unknown significance, but occurs more frequently in CRF01_AE. 18 In South Africa, PIs are employed in adult second line treatment regimens and in first line treatment for children less than 3 years old. It is expected that 15-20% of adults will experience virologic failure with the first line regimen comprising RT inhibitors in the first 2 years of the program, 19 and thus the use of PIs is likely to increase. Against the backdrop of the presence of multiple minor and polymorphic resistance-related mutations in drug inexperienced patients, the question that needs to be addressed is whether these will affect viral susceptibility to PIs, and to what extent does this baseline profile affect the development of resistant viruses. In the present study involving drug inexperienced patients K20R, M36I, L63P/A/S/T/V, and I93L occurred in high frequencies in agreement with a previous report. 20 In a study comparing treatment outcomes in Israel with nelfinavir, a significant accumulation of M36I, L63P, and I93L substitutions occurred in patients infected with HIV-1-C compared to HIV-1-B, and these mutations correlated with reduced replicative capacities. In addition, it was noted that HIV-1-C does not select for the D30N mutation upon exposure to nelfinavir as does HIV-1-B, 21 indicating different mutation evolutionary pathways.
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Although candidate PIs modeled against HIV-1-B are evaluated for other subtypes, because of the primary differences in the baseline nucleotide sequences, viruses may be evolving along different pathways and using different mechanisms for resistance development. Mutations, some of which occur in the active site, substrate cleft, and substrate flap, and occur more frequently in C viruses, do influence enzyme activity, efficiency, and, consequently, the effectiveness of PIs. The relative proportions of B viruses is decreasing, representing less than 12% of global infections, while C viruses are gaining worldwide distribution and accounting for more than 50% of total infections, with Southern Africa bearing the heaviest burden. Designing and developing future anti-HIV drugs should target the expanding circulating variants. In addition, more investigations are required to fully evaluate the importance of C viruses harboring multiple resistance-related polymorphisms with respect to their sensitivity and subsequent evolution in the presence of drug pressure. With the possibility of complicated mutations arising in treated patients, the impact of this and other signature mutations in subtype C viruses needs to be defined in this evolving and dynamic epidemic so that salvage therapies may be designed as required. This study adds to existing data indicating that resistant viruses among drug inexperienced patients are not common in South Africa, although this may change in the near future as more patients receive antiretroviral treatment.
SEQUENCE DATA
The nucleotide sequences described in this study have been deposited in GenBank with the following accession numbers: DQ222243-222282 (protease) and DQ222283-DQ222317 (reverse transcriptase).
